10 results about "Isotonic Solutions" patented technology

The invention discloses a PDRNamp and a method for preparing the PDRNamp. The invention discloses EGT eye wash as well as a preparation method and application thereof, and belongs to the technical field of eye care products. The eye wash is prepared from the following active components in percentage by mass: 0.001 to 0.01 percent of PDRN, 0.03 to 0.1 percent of EGT (Ergothioneine), sodium hyaluronate, sodium chloride, taurine and the like, wherein the mass percent of the PDRN is 0.001 to 0.01 percent, and the mass percent of the EGT is 0.03 to 0.1 percent. Through the synergistic effect of PDRN and EGT, the product has excellent cornea repairing capacity and a powerful anti-oxidation function at the same time, and the moisturizing and soothing effects are enhanced by compounding sodium hyaluronate and taurine. The obtained eye washing liquid is an isotonic solution with neutral pH, is mild and non-irritating, does not contain preservatives, can effectively achieve multiple nursing effects of eye cleaning, moisturizing, repairing, anti-inflammatory and anti-oxidation, and is suitable for relieving xerophthalmia, assisting cornea repair and daily anti-oxidation nursing of eyes.

The invention discloses an irinotecan and afatinib maleate co-loaded liposome preparation as well as a preparation method and application thereof, irinotecan and afatinib maleate are taken as effective components of the liposome, and the liposome comprises a liposome carrier, an inner water phase positioned in a liposome membrane and an outer water phase positioned outside the liposome membrane; the irinotecan and the afatinib maleate are encapsulated in the inner water phase; the inner water phase comprises an ammonium salt aqueous solution, and an ammonium salt gradient exists between the inner water phase in the liposome membrane and the outer water phase outside the liposome membrane; the outer water phase is a physiological isotonic solution. According to the present invention, the research results show that the irinotecan and afatinib maleate co-carrying liposome can simultaneously deliver the two drugs with the synergistic ratio into the same tumor cell compared to the irinotecan single drug liposome and the afatinib maleate single drug liposome so as to maximize the synergistic effect of the drugs, and significantly improve the anti-tumor effect;

An ex vivo test system 10 is constituted of a fluid circuit that circulates a prescribed circulation liquid by simulating the blood circulation state of a human body, and comprises a circulation liquid maintenance unit 17 that maintains, in the same manner as the blood environment in vivo, chemical factors in the circulation liquid, which affect the performance evaluation of a test object S. The circulation liquid maintenance unit 17 comprises: a replenishing liquid unit 23 that maintains the chloride ion concentration and protein concentration of the circulation liquid at desired values by injecting a replenishing liquid composed of an electrolyte-free isotonic solution into the fluid circuit; and a carbon dioxide supply unit 24 that maintains the pH of the circulation liquid at a desired value by supplying carbon dioxide into the fluid circuit, the state of the circulation liquid being maintained while compensating for the effect of moisture loss during circulation of the circulation liquid.

The present invention addresses the problem of providing a cryopreservation fluid for cells and a fluid for application to mammalian cells, capable of cryopreserving such cells and effectively suppressing cell death after thawing, as well as a method for cryopreserving mammalian cells using said fluid. Cell death after thawing can be suppressed more effectively than with conventional mammalian cell cryopreservation fluids when using an isotonic solution comprising: 2.0 to 6.0% (w / v) trehalose or a derivative thereof, or a salt of trehalose or a derivative thereof; 4.0 to 7.0% (w / v) dextran or a derivative thereof, or a salt of dextran or a derivative thereof; and DMSO or glycerin as the cryopreservation fluid for mammalian cells or as the fluid for application to mammalian cells, and the mammalian cells are cryopreserved in said fluid.

A stable AST-3424 injection preparation, being a solution containing 0.1-200 mg / ml or 1-200 mg / ml of AST-3424 active pharmaceutical ingredient. A solvent in the solution contains a C2-C8 monohydric alcohol. The preparation method comprises the following steps: subjecting the AST-3424 active pharmaceutical ingredient and a partial prescription volume of ethanol to a first dissolution and formulation; adding a prescription volume of propylene glycol for a second dissolution and formulation; and then adding the remaining prescription volume of ethanol for mixing and dissolving to obtain a solution containing 1-200 mg / ml of AST-3424 active pharmaceutical ingredient. Provided is an AST-3424 injection for injection, wherein the solvent is water, a glucose solution, ethanol, or propylene glycol, the solutes consist of the AST-3424 active pharmaceutical ingredient, an isotonic regulator, and a pH regulator. The concentration of the AST-3424 active pharmaceutical ingredient of the injection is 0.001-1.000 mg / ml, the pH of the injection is 6.8-10.5, and the solution is an isotonic solution.

The application discloses a kind of liquid guide laser bone ablation devices and methods of multi-modal sensing fusion, the liquid guide laser bone ablation device includes: supply module, ablation module, detection module and main control module, supply module includes containing cavity and nozzle, nozzle is located at the bottom of containing cavity, the isotonic solution in containing cavity can be ejected by nozzle and be flushed with liquid beam flow to be ablated tissue.Ablation module includes pulsed laser, pulsed laser is used to emit ablation laser in liquid beam flow, and liquid beam flow guides ablation laser to remove to be ablated tissue.Detection module includes frequency-sweeping laser and balanced optical detector, frequency-sweeping laser is used to emit probe laser in liquid beam flow, and balanced optical detector is used to receive the surface scattering of to be ablated tissue probe laser, and is converted into electrical signal.Main control module is used to determine the phase change data generated by light-heat expansion of to be ablated tissue based on electrical signal, determines the ablation depth of to be ablated tissue and calculates temperature.Realize the deep hole ablation of low taper.

The invention discloses an injection preparation, compatible liquid medicine and a preparation method thereof. The injection preparation and the compatible liquid medicine provided by the invention meet the requirements of long-term clinical tests and commercial production and sales through tests. The injection preparation is a solution containing a compound shown in the formula I, and a solvent of the solution contains C2-C8 alcohol and can also contain other cosolvents or solubilizers. A preferable injection preparation is a mixed solution containing 10mg / ml of the compound shown in the formula (I), DMA, ELP and ethanol, DMA is a cosolvent, and ELP is a solubilizer. A solvent of the ready-to-use injection (compatible liquid medicine) of the compound shown in the formula (I) is water, solutes of the ready-to-use injection comprise the compound shown in the formula I, DMA, ELP, ethyl alcohol, an isotonic regulating reagent and a pH regulator, the concentration of the compound A in the injection is 0.016-1.10 mg / ml, the pH of the injection is 7.4, and the injection is an isotonic solution. In addition, the invention also discloses a preparation method of the injection preparation and the compatible liquid medicine thereof.

The invention discloses treprostinil multivesicular liposome for treating pulmonary arterial hypertension. The multivesicular liposome is prepared from an inner water phase, an oil phase and an outer water phase through a double emulsification method, the treprostinil is dissolved in the inner water phase; the oil phase comprises soybean lecithin, cholesterol, glyceryl trioleate and electronegative lipid; the inner water phase and the outer water phase are body fluid isotonic solutions. The treprostinil multivesicular liposome disclosed by the invention has good stability and high encapsulation efficiency, obviously reduces burst release effect, shows obvious slow release characteristic, is beneficial to prolonging in-vivo drug half-life period, and can realize 48-hour treatment, reduce administration frequency, simplify administration method and improve patient compliance through simple subcutaneous injection. After the treprostinil multivesicular liposome is injected once, the inflammatory reaction of the injection part can be eliminated within 7 days, and the treprostinil multivesicular liposome has good safety.

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.